Revenue Recognition - Schedule of Revenue by Product (Details) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
		Jun. 29, 2019	Jun. 30, 2018	Jun. 29, 2019	Jun. 30, 2018
Disaggregation of Revenue [Line Items]
Net sales	[1]	$ 1,149.0	$ 1,186.4	$ 2,323.5	$ 2,403.4
CSCA
Disaggregation of Revenue [Line Items]
Net sales	[2]	582.1	596.9	1,163.9	1,198.5
CSCA | Cough/Cold/Allergy/Sinus
Disaggregation of Revenue [Line Items]
Net sales	[2]	120.9	109.3	253.5	250.8
CSCA | Gastrointestinal
Disaggregation of Revenue [Line Items]
Net sales	[2]	106.2	103.0	206.5	195.2
CSCA | Infant nutritionals
Disaggregation of Revenue [Line Items]
Net sales	[2]	85.5	109.2	181.5	212.6
CSCA | Analgesics
Disaggregation of Revenue [Line Items]
Net sales	[2]	88.2	92.2	177.0	185.9
CSCA | Smoking cessation
Disaggregation of Revenue [Line Items]
Net sales	[2]	77.0	71.2	143.8	137.1
CSCA | Animal health
Disaggregation of Revenue [Line Items]
Net sales	[2]	22.4	31.9	42.0	58.2
CSCA | Vitamins, Minerals and Dietary Supplements
Disaggregation of Revenue [Line Items]
Net sales	[2]	3.9	4.3	7.3	7.3
CSCA | Other CSCA
Disaggregation of Revenue [Line Items]
Net sales	[2],[3]	78.0	75.8	152.3	151.4
CSCI
Disaggregation of Revenue [Line Items]
Net sales		327.5	357.9	678.3	735.7
CSCI | Cough, Cold, and Allergy
Disaggregation of Revenue [Line Items]
Net sales		74.1	84.7	169.8	183.4
CSCI | Lifestyle
Disaggregation of Revenue [Line Items]
Net sales		81.2	86.1	162.7	175.8
CSCI | Personal care and derma-therapeutics
Disaggregation of Revenue [Line Items]
Net sales		69.2	79.7	135.2	155.3
CSCI | Natural Health and Vitamins, Minerals and Dietary Supplements
Disaggregation of Revenue [Line Items]
Net sales		25.6	27.9	55.4	61.1
CSCI | Anti-Parasite
Disaggregation of Revenue [Line Items]
Net sales		26.0	30.4	52.7	58.5
CSCI | Other CSCI
Disaggregation of Revenue [Line Items]
Net sales	[4]	51.4	49.1	102.5	101.6
RX
Disaggregation of Revenue [Line Items]
Net sales		$ 239.4	$ 231.6	$ 481.3	$ 469.2

[1] Derived from the location of the entity that sells to a third party.

[2] Includes net sales from our OTC contract manufacturing business.

[3] Consists primarily of branded OTC, diabetic care, diagnostic products and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.

[4] Consists primarily of liquid licensed products, our distribution business and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.